PepGen Inc. (PEPG)
NASDAQ
Market Cap
$548.5M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
14 of 809
Rank in Industry
11 of 445
Largest Insider Buys in Sector
PEPG Stock Price History Chart
PEPG Stock Performance
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Activity of PepGen Inc.
Over the last 12 months, insiders at PepGen Inc. have bought $27.22M and sold $487,624 worth of PepGen Inc. stock.
On average, over the past 5 years, insiders at PepGen Inc. have bought $21.66M and sold $551,774 worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $680.32M. McArthur James G (President and CEO) — $7,056.
The last purchase of 2,557,593 shares for transaction amount of $27.21M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑02‑09.
List of Insider Buy and Sell Transactions, PepGen Inc.
| 2024-06-24 | Sale | Mellion Michelle L | Chief Medical Officer | 9,260 0.0291% | $18.19 | $168,427 | -6.00% | |
| 2024-06-12 | Sale | Mellion Michelle L | Chief Medical Officer | 1,086 0.0034% | $18.06 | $19,615 | -3.13% | |
| 2024-06-11 | Sale | Mellion Michelle L | Chief Medical Officer | 500 0.0016% | $18.04 | $9,022 | -3.74% | |
| 2024-06-06 | Sale | Mellion Michelle L | SVP, Clinical Development | 1,411 0.0045% | $18.00 | $25,398 | -0.17% | |
| 2024-06-05 | Sale | Mellion Michelle L | SVP, Clinical Development | 7,245 0.0223% | $18.09 | $131,062 | -4.41% | |
| 2024-05-17 | Sale | Svenstrup Niels | SVP, Chem. Mfg & Controls | 10,000 0.0306% | $13.41 | $134,100 | +26.57% | |
| 2024-02-09 | RA CAPITAL MANAGEMENT, L.P. | 2.56M 10.4935% | $10.64 | $27.21M | -4.57% | |||
| 2023-11-30 | McArthur James G | President and CEO | 1,694 0.006% | $4.17 | $7,056 | +169.90% | ||
| 2023-06-08 | Sale | McArthur James G | President and CEO | 2,381 0.0098% | $16.04 | $38,188 | -54.91% | |
| 2023-06-07 | Sale | McArthur James G | President and CEO | 8,419 0.0366% | $16.23 | $136,618 | -52.77% | |
| 2023-06-06 | Sale | McArthur James G | President and CEO | 18,150 0.076% | $16.18 | $293,660 | -54.30% | |
| 2023-06-05 | Sale | McArthur James G | President and CEO | 500 0.0022% | $16.06 | $8,028 | -52.58% | |
| 2023-06-02 | Sale | McArthur James G | President and CEO | 1,800 0.0075% | $16.04 | $28,863 | -54.46% | |
| 2023-03-24 | Sale | Goyal Jaya | EVP, Res. & Preclin. Dev. | 392 0.0022% | $20.00 | $7,840 | -51.74% | |
| 2023-02-08 | Sale | Goyal Jaya | EVP, Res. & Preclin. Dev. | 644 0.0027% | $17.00 | $10,948 | -56.96% | |
| 2023-02-07 | Sale | Goyal Jaya | EVP, Res. & Preclin. Dev. | 3,679 0.0154% | $17.18 | $63,213 | -57.26% | |
| 2023-02-06 | Sale | Goyal Jaya | EVP, Res. & Preclin. Dev. | 1,677 0.0071% | $17.04 | $28,568 | -56.43% | |
| 2022-05-10 | Oxford Science Enterprises plc | 10 percent owner | 879,970 6.7212% | $12.00 | $10.56M | |||
| 2022-05-10 | Shah Rajeev M. | 249,749 1.9076% | $12.00 | $3M | +7.35% | |||
| 2022-05-10 | Deerfield Private Design Fund V, L.P. | 208,333 1.5913% | $12.00 | $2.5M | +7.35% |
Insider Historical Profitability
2.42%
| RA CAPITAL MANAGEMENT, L.P. | 9179273 38.5464% | $16.92 | 1 | 0 | ||
| McArthur James G | President and CEO | 1694 0.0071% | $16.92 | 1 | 5 | |
| Svenstrup Niels | SVP, Chem. Mfg & Controls | 0 0% | $16.92 | 0 | 1 | |
| Mellion Michelle L | SVP, Clinical Development | 0 0% | $16.92 | 0 | 5 | |
| Oxford Science Enterprises plc | 10 percent owner | 4755388 14.6978% | $16.92 | 1 | 0 | |
| Shah Rajeev M. | 1302600 5.47% | $16.92 | 1 | 0 | +7.35% | |
| Deerfield Private Design Fund V, L.P. | 476813 2.0023% | $16.92 | 1 | 0 | +7.35% | |
| KEATING LAURIE | director | 4166 0.0175% | $16.92 | 1 | 0 | <0.0001% |
| Goyal Jaya | EVP, Res. & Preclin. Dev. | 0 0% | $16.92 | 0 | 4 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| RA Capital Management, L.P. | $157.14M | 32.98 | 10.69M | +31.45% | +$37.6M | 0.16 | |
| Suvretta Capital Management, LLC | $22.36M | 4.69 | 1.52M | +212.56% | +$15.2M | 0.94 | |
| Frazier Life Sciences Management L P | $22.09M | 4.64 | 1.5M | New | +$22.09M | 1.13 | |
| Viking Global Investors | $21.79M | 4.57 | 1.48M | 0% | +$0 | 0.01 | |
| Perceptive Advisors | $20.73M | 4.35 | 1.41M | New | +$20.73M | 0.01 | |
| Adage Capital Partners Gp L L C | $19.6M | 4.11 | 1.33M | +21.24% | +$3.43M | 0.04 | |
| Janus Henderson | $17.23M | 3.6 | 1.17M | +18.06% | +$2.63M | 0.01 | |
| The Vanguard Group | $12.5M | 2.62 | 850,445 | +68.01% | +$5.06M | <0.0001 | |
| Laurion Capital Management LP | $12.37M | 2.6 | 841,431 | +26.62% | +$2.6M | 0.35 | |
| BlackRock | $11.49M | 2.41 | 781,437 | +8% | +$851,115.31 | <0.0001 | |
| Sofinnova | $7.4M | 1.55 | 503,624 | +2,086.06% | +$7.06M | 0.02 | |
| Fidelity Investments | $6.74M | 1.42 | 458,640 | -37.86% | -$4.11M | <0.0001 | |
| Octagon Capital Advisors LP | $5.53M | 1.16 | 376,117 | New | +$5.53M | 0.72 | |
| Geode Capital Management | $4.4M | 0.92 | 299,487 | +42.58% | +$1.31M | <0.0001 | |
| State Street | $3.54M | 0.74 | 240,982 | +11.1% | +$353,799.56 | <0.0001 | |
| Artal Group S A | $2.94M | 0.62 | 200,000 | New | +$2.94M | 0.02 | |
| Point72 Asset Management | $2.83M | 0.59 | 192,178 | New | +$2.83M | 0.01 | |
| Bridgeway Capital Management | $1.46M | 0.31 | 99,200 | 0% | +$0 | 0.03 | |
| Northern Trust | $1.36M | 0.28 | 92,195 | +23.21% | +$255,338.91 | <0.0001 | |
| Monashee Investment Management LLC | $1.26M | 0.27 | 85,886 | New | +$1.26M | 0.11 | |
| Walleye Capital | $949,826.00 | 0.2 | 64,614 | New | +$949,826.00 | <0.01 | |
| Citigroup | $596,967.00 | 0.13 | 40,610 | +2,864.23% | +$576,828.00 | <0.0001 | |
| Crestline Management Lp | $514,500.00 | 0.11 | 35,000 | New | +$514,500.00 | 0.05 | |
| Rathbone Brothers | $470,444.00 | 0.1 | 32,003 | -48.38% | -$440,999.91 | <0.01 | |
| Charles Schwab | $459,963.00 | 0.1 | 31,290 | +12.59% | +$51,450.00 | <0.0001 | |
| BNY Mellon | $452,172.00 | 0.1 | 30,760 | -2.09% | -$9,672.60 | <0.0001 | |
| Morgan Stanley | $418,685.00 | 0.09 | 28,482 | -20.7% | -$109,294.40 | <0.0001 | |
| Qube Research & Technologies | $364,354.00 | 0.08 | 24,786 | +20,051.22% | +$362,545.90 | <0.0001 | |
| Bank of America | $280,138.00 | 0.06 | 19,057 | +20.69% | +$48,024.92 | <0.0001 | |
| American Century Investments | $245,519.00 | 0.05 | 16,702 | New | +$245,519.00 | <0.0001 | |
| JPMorgan Chase | $227,586.00 | 0.05 | 15,482 | +52.64% | +$78,483.51 | <0.0001 | |
| Nuveen | $203,566.00 | 0.04 | 13,848 | 0% | +$0 | <0.0001 | |
| RhumbLine Advisers | $203,602.00 | 0.04 | 13,851 | +0.07% | +$146.99 | <0.0001 | |
| Goldman Sachs | $194,231.00 | 0.04 | 13,213 | -6.66% | -$13,862.09 | <0.0001 | |
| AllianceBernstein | $177,282.00 | 0.04 | 12,060 | 0% | +$0 | <0.0001 | |
| UBS | $147,838.00 | 0.03 | 10,057 | -7.85% | -$12,597.91 | <0.0001 | |
| Barclays | $103,000.00 | 0.02 | 7,003 | -48.97% | -$98,852.35 | <0.0001 | |
| New York State Common Retirement Fund | $95,000.00 | 0.02 | 6,480 | -0.05% | -$43.98 | <0.0001 | |
| MetLife Investment Management | $85,172.00 | 0.02 | 5,794 | New | +$85,172.00 | <0.01 | |
| American International Group | $72,809.00 | 0.02 | 4,953 | -0.86% | -$632.10 | <0.0001 | |
| Deutsche Bank | $62,166.00 | 0.01 | 4,229 | New | +$62,166.00 | <0.0001 | |
| Wells Fargo | $51,097.00 | 0.01 | 3,476 | +16.88% | +$7,379.37 | <0.0001 | |
| Ohio Strs | $52,000.00 | 0.01 | 3,600 | +89.47% | +$24,555.56 | <0.0001 | |
| Acadian Asset Management | $30,000.00 | 0.01 | 2,052 | New | +$30,000.00 | <0.0001 | |
| Ameritas Investment Partners Inc | $17,273.00 | <0.01 | 1,175 | 0% | +$0 | <0.01 | |
| CalSTRS | $14,847.00 | <0.01 | 1,010 | -38.94% | -$9,466.80 | <0.0001 | |
| Legal & General | $12,539.00 | <0.01 | 853 | 0% | +$0 | <0.0001 | |
| MetLife | $8,761.00 | <0.01 | 596 | New | +$8,761.00 | <0.0001 | |
| Amalgamated Bank | $5,000.00 | <0.01 | 337 | -72.22% | -$12,997.03 | <0.0001 | |
| Tower Research Capital | $3,954.00 | <0.01 | 269 | -84.72% | -$21,916.04 | <0.0001 |